


# Proton Pump





HDAC Inhibitor:  
Vorinostat (SAHA)




HDAC (Histone deacetylase)

Proton pump is an integral membrane protein that is capable of moving protons across a biological membrane. Mechanisms are based on conformational changes of the protein structure or on the Q cycle. In cell respiration, the proton pump uses energy to transport protons from the matrix of the mitochondrion to the inter-membrane space. It is an active pump, that generates a proton concentration gradient across the inner mitochondrial membrane, because there are more protons outside the matrix than inside. The difference in pH and electric charge (ignoring differences in buffer capacity) creates an electrochemical potential difference that works similar to that of a battery or energy storing unit for the cell. The process could also be seen as analogous to cycling uphill or charging a battery for later use, as it produces potential energy. The proton pump does not create energy, but forms a gradient that stores energy for later use.

## Proton Pump Inhibitors & Modulators

<p><b>(R)-Lansoprazole</b> (Dexlansoprazole) <span style="float: right;">Cat. No.: HY-13662B</span></p> <p><b>Bioactivity:</b> (R)-Lansoprazole is a proton pump inhibitor which prevents the stomach from producing acid. Target: Proton Pump Lansoprazole sodium is sodium salt form of lansoprazole, lansoprazole, a substituted benzimidazole proton pump inhibitor, on pharmacokinetics and metabolism of theophylline has been...</p> <p><b>Purity:</b> 98.0% <b>Clinical Data:</b> Launched <b>Size:</b> 100 mg, 500 mg</p> 	<p><b>Bafilomycin A1</b> (-)-Bafilomycin A1) <span style="float: right;">Cat. No.: HY-100558</span></p> <p><b>Bioactivity:</b> Bafilomycin A1, a macrolide antibiotic isolated from the Streptomyces species, is a specific inhibitor of <b>vacuolar-type H+ ATPase</b>. Bafilomycin A1 inhibits <b>autophagy</b> [1].</p> <p><b>Purity:</b> 99.0% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 100u g</p> 
<p><b>Bamaquimast</b> (F 10126; L 0042) <span style="float: right;">Cat. No.: HY-101427</span></p> <p><b>Bioactivity:</b> Bamaquimast is an inhibitor of <b>proton pump</b> extracted from patent US2005165041, example 138.</p> <p><b>Purity:</b> 98.79% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p><b>Chebulinic acid</b> <span style="float: right;">Cat. No.: HY-N2033</span></p> <p><b>Bioactivity:</b> Chebulinic acid is a potent natural inhibitor of M. tuberculosis DNA gyrase, also can inhibit SMAD-3 phosphorylation, inhibit H+ K+-ATPase activity.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 5 mg, 10 mg</p> 
<p><b>Esomeprazole magnesium</b> (S)-Omeprazole magnesium; (-)-Omeprazole magnesium) <span style="float: right;">Cat. No.: HY-B1446</span></p> <p><b>Bioactivity:</b> Esomeprazole magnesium is an inhibitor of <b>H<sup>+</sup>, K<sup>+</sup>-ATPase</b>, effectively used in the research of upper intestinal disorder.</p> <p><b>Purity:</b> 98.0% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10mM x 1mL in DMSO, 50 mg</p> 	<p><b>Esomeprazole magnesium salt</b> <span style="float: right;">Cat. No.: HY-17021A</span></p> <p><b>Bioactivity:</b> Esomeprazole magnesium salt is a proton pump inhibitor which reduces acid secretion through inhibition of the H+ / K+ ATPase in gastric parietal cells. IC50 value: Target: proton pump Esomeprazole magnesium salt is a proton pump inhibitor and gastric antisecretory agent indicated for the short-term...</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> Launched <b>Size:</b> 5 mg, 10 mg</p> 
<p><b>Esomeprazole Magnesium trihydrate</b> (S)-Omeprazole magnesium trihydrate) <span style="float: right;">Cat. No.: HY-17022</span></p> <p><b>Bioactivity:</b> Esomeprazole Magnesium trihydrate is a proton pump inhibitor which reduces acid secretion through inhibition of the H+ / K+ ATPase in gastric parietal cells. IC50 value: Target: proton pump Esomeprazole sodium (Nexium) is the S-isomer of omeprazole and acts as a proton pump inhibitor and gastric...</p> <p><b>Purity:</b> 95.0% <b>Clinical Data:</b> Launched <b>Size:</b> 50 mg, 100 mg, 200 mg, 500 mg</p> 	<p><b>Esomeprazole potassium salt</b> (S)-Omeprazole potassium) <span style="float: right;">Cat. No.: HY-17021B</span></p> <p><b>Bioactivity:</b> Esomeprazole potassium salt is a proton pump inhibitor which reduces acid secretion through inhibition of the H+ / K+ ATPase in gastric parietal cells.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> Launched <b>Size:</b> 50 mg, 100 mg</p> 
<p><b>Esomeprazole sodium</b> (S)-Omeprazole sodium) <span style="float: right;">Cat. No.: HY-17023</span></p> <p><b>Bioactivity:</b> Esomeprazole sodium is a proton pump inhibitor which reduces acid secretion through inhibition of the H+ / K+ ATPase in gastric parietal cells. IC50 value: Target: proton pump Esomeprazole sodium (Nexium) is the S-isomer of omeprazole and acts as a proton pump inhibitor and gastric antisecretory...</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> Launched <b>Size:</b> 5 mg, 10 mg, 50 mg</p> 	<p><b>Ilaprazole</b> (IY-81149) <span style="float: right;">Cat. No.: HY-101664</span></p> <p><b>Bioactivity:</b> Ilaprazole (IY-81149) is a <b>proton pump</b> inhibitor; inhibits H<sup>+</sup>/K<sup>+</sup>-ATPase with an <b>IC<sub>50</sub></b> of 6.0 μM.</p> <p><b>Purity:</b> 98.0% <b>Clinical Data:</b> Launched <b>Size:</b> 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg</p> 

<p><b>Lansoprazole</b> (AG-1749) <span style="float: right;">Cat. No.: HY-13662</span></p> <p><b>Bioactivity:</b> Lansoprazole(AG 1749) is a proton pump inhibitor which prevents the stomach from producing acid.</p> <p><b>Purity:</b> 98.0% <b>Clinical Data:</b> Launched <b>Size:</b> 10mM x 1mL in DMSO, 1 g, 5 g</p> 	<p><b>Lansoprazole sodium</b> (AG-1749 sodium) <span style="float: right;">Cat. No.: HY-13662A</span></p> <p><b>Bioactivity:</b> Lansoprazole sodium(AG-1749) is a proton pump inhibitor which prevents the stomach from producing acid.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> Launched <b>Size:</b> 1 g, 5 g</p> 
<p><b>Linaprazan</b> (AZD0865) <span style="float: right;">Cat. No.: HY-100412</span></p> <p><b>Bioactivity:</b> AZD0865 inhibits gastric H<sup>+</sup>,K<sup>+</sup>-ATPase by K<sup>+</sup>-competitive binding. (IC<sub>50</sub>: 1.0 ± 0.2 μM) It is an acid-suppressing agent with rapid onset of action and potent acid inhibition. In vitro: AZD0865 can inhibit the final step in acid secretion. AZD0865 reduced porcine renal Na<sup>+</sup>,K<sup>+</sup>-ATPase activity by 9 ± ...</p> <p><b>Purity:</b> 98.51% <b>Clinical Data:</b> Phase 2 <b>Size:</b> 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p><b>Omeprazole</b> (H 16868) <span style="float: right;">Cat. No.: HY-B0113</span></p> <p><b>Bioactivity:</b> Omeprazole (H 16868) is a proton pump inhibitor used in the treatment of dyspepsia.</p> <p><b>Purity:</b> 97.06% <b>Clinical Data:</b> Launched <b>Size:</b> 10mM x 1mL in DMSO, 100 mg, 500 mg</p> 
<p><b>Omeprazole D3</b> (H 16868 D3) <span style="float: right;">Cat. No.: HY-B0113S</span></p> <p><b>Bioactivity:</b> Omeprazole D3 (H 16868 D3) is deuterium labeled Omeprazole, which is a proton pump inhibitor used in the treatment of dyspepsia.</p> <p><b>Purity:</b> 98.0% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg</p> 	<p><b>Pantoprazole</b> (BY1023; SKF96022) <span style="float: right;">Cat. No.: HY-17507</span></p> <p><b>Bioactivity:</b> Pantoprazole(SKF96022; Protonix) is a proton pump inhibitor drug used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease. IC<sub>50</sub> value: Target: proton pump inhibitor</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> Launched <b>Size:</b> 100 mg, 500 mg</p> 
<p><b>Pantoprazole sodium</b> (BY1023 (sodium); SKF96022 (sodium)) <span style="float: right;">Cat. No.: HY-17507A</span></p> <p><b>Bioactivity:</b> Pantoprazole sodium salt(SKF96022; Protonix) is a proton pump inhibitor drug used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease. IC<sub>50</sub> value: Target: proton pump inhibitor</p> <p><b>Purity:</b> 98.0% <b>Clinical Data:</b> Launched <b>Size:</b> 10mM x 1mL in Water, 100 mg, 500 mg</p> 	<p><b>Pantoprazole sodium hydrate</b> (BY1023 (sodium hydrate); SKF96022 (sodium hydrate)) <span style="float: right;">Cat. No.: HY-17507B</span></p> <p><b>Bioactivity:</b> Pantoprazole sodium hydrate is a proton pump inhibitor drug used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease. IC<sub>50</sub> value: Target: proton pump inhibitor</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> Launched <b>Size:</b> 100 mg, 500 mg</p> 
<p><b>Picoprazole</b> <span style="float: right;">Cat. No.: HY-15384</span></p> <p><b>Bioactivity:</b> Picoprazole is a specific inhibitor of H<sup>+</sup>/K<sup>+</sup>-ATPase with IC<sub>50</sub> of 3.1±0.4 μM.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg, 10 mg, 20 mg</p> 	<p><b>Pumaprazole</b> (BY-841) <span style="float: right;">Cat. No.: HY-19223</span></p> <p><b>Bioactivity:</b> Pumaprazole is a reversible <b>proton pump</b> antagonist.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg, 10 mg</p> 

<p><b>Rabeprazole</b> (LY307640) <span style="float: right;">Cat. No.: HY-B0656</span></p> <p><b>Bioactivity:</b> Rabeprazole is an antiulcer drug in the class of proton pump inhibitors.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> Launched <b>Size:</b> 10 mg, 50 mg</p> 	<p><b>Rabeprazole sodium</b> (LY307640 sodium) <span style="float: right;">Cat. No.: HY-B0656A</span></p> <p><b>Bioactivity:</b> Rabeprazole sodium(LY307640 sodium) is an antiulcer drug in the class of proton pump inhibitors.</p> <p><b>Purity:</b> 98.0% <b>Clinical Data:</b> Launched <b>Size:</b> 10mM x 1mL in DMSO, 10 mg, 50 mg</p> 
<p><b>S3337</b> <span style="float: right;">Cat. No.: HY-U00222</span></p> <p><b>Bioactivity:</b> S3337 is an H<sup>+</sup>, K<sup>+</sup>-ATPase inhibitor.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg, 10 mg, 20 mg</p> 	<p><b>SKF96067</b> <span style="float: right;">Cat. No.: HY-U00042</span></p> <p><b>Bioactivity:</b> SKF96067 is a reversible inhibitor of the gastric H<sup>+</sup>/K<sup>+</sup>-ATPase.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg, 10 mg, 20 mg</p> 
<p><b>Soraprazan</b> (BYK61359) <span style="float: right;">Cat. No.: HY-100414</span></p> <p><b>Bioactivity:</b> Soraprazan is a reversible, and fast-acting inhibitor of gastric H<sup>+</sup>/K<sup>+</sup> ATPase.</p> <p><b>Purity:</b> 99.02% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 	<p><b>Tegoprazan</b> <span style="float: right;">Cat. No.: HY-17623</span></p> <p><b>Bioactivity:</b> Tegoprazan, a potassium-competitive acid blocker, is a potent, oral active and highly selective inhibitor of gastric H<sup>+</sup>/K<sup>+</sup>-ATPase that could control gastric acid secretion and motility, with IC<sub>50</sub> values ranging from 0.29-0.52 μM ...</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 250 mg, 500 mg</p> 
<p><b>Tenatoprazole sodium</b> (Tenatoprazole sodium salt) <span style="float: right;">Cat. No.: HY-17421A</span></p> <p><b>Bioactivity:</b> Tenatoprazole sodium (TU-199 sodium) is a <b>proton pump</b> inhibitor; inhibits hog gastric H<sup>+</sup>/K<sup>+</sup>-ATPase with an IC<sub>50</sub> of 6.2 μM.</p> <p><b>Purity:</b> &gt;98% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 1 mg, 5 mg, 10 mg, 20 mg</p> 	<p><b>Vonoprazan</b> (TAK-438) <span style="float: right;">Cat. No.: HY-100007</span></p> <p><b>Bioactivity:</b> TAK-438 (free base) is a novel P-CAB (potassium-competitive acid blocker) that reversibly inhibits H<sup>+</sup>/K<sup>+</sup> ATPase with IC<sub>50</sub> of 19 nM (pH 6.5), controls gastric acid secretion. IC<sub>50</sub> value: 19 nM [1] Target: H<sup>+</sup>/K<sup>+</sup> ATPase in vitro: TAK-438 is a pyrrole derivative with a chemical structure that is...</p> <p><b>Purity:</b> 99.33% <b>Clinical Data:</b> Launched <b>Size:</b> 10mM x 1mL in DMSO, 50 mg, 100 mg</p> 
<p><b>Vonoprazan Fumarate</b> (TAK-438) <span style="float: right;">Cat. No.: HY-15295</span></p> <p><b>Bioactivity:</b> Vonoprazan Fumarate (TAK-438) is an orally active <b>potassium-competitive acid blocker</b> which inhibits H<sup>+</sup>, K<sup>+</sup>-ATPase activity with an IC<sub>50</sub> of 19 nM.</p> <p><b>Purity:</b> 99.97% <b>Clinical Data:</b> Launched <b>Size:</b> 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p><b>Zinc Pyrithione</b> <span style="float: right;">Cat. No.: HY-B0572</span></p> <p><b>Bioactivity:</b> Zinc Pyrithione is an antifungal and antibacterial agent disrupting membrane transport by blocking the proton pump. Target: Proton Pump Zinc pyrithione is considered as a coordination complex of zinc. The pyrithione ligands, which are formally monoanions, are chelated to Zn<sup>2+</sup> via oxygen and...</p> <p><b>Purity:</b> 98.0% <b>Clinical Data:</b> No Development Reported <b>Size:</b> 10mM x 1mL in DMSO, 1 g, 5 g</p> 